The firm is investing 21m CHF ($21.7m) in the site, which will see the 1,415m² facility expand to 2,905m².
Managing director Stefano Console told us the decision to expand came from growing market demand, predominantly in Europe and North America.
The company’s founder Michele Müller also observed an increased demand for fill & finish services.
“Both GMP spray drying as a particle engineering technique and low dose capsule filling are becoming increasingly popular across the market and at present there are very few CDMOs [contract development and manufacturing organisations] offering this level of capability,” said Müller.
“From our expanded facility, we will continue to produce both clinical and commercial products, with a particular specialism in dry powder inhalers,” he added.
New business & jobs
Console said he expects the increased GMP capabilities to increase the company’s client base, which currently includes firms in the US, Europe, New Zealand and Asia.
“The expansion is already attracting new business, and we expect this to continue in the coming months,” he said.
The expanded facility - expected to be operational by Q4 2017 - will create 20 new roles, he told us.